Ozempic vs Mounjaro for Weight Loss: Dosing & Results Guide
TL;DR
- Both semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are injectable GLP-1-based therapies used for weight management, but they work through different mechanisms.
- In clinical trials, tirzepatide produced greater average weight loss (~20–21% at the highest dose) compared with semaglutide (~15% at the approved weight-loss dose).
- Tirzepatide is a dual GIP/GLP-1 receptor agonist; semaglutide targets GLP-1 alone.
- GI side effects — nausea, vomiting, diarrhea, constipation — are the most common adverse events with both drugs and are generally transient during dose escalation.
- Cost without insurance is high for both (roughly $900–$1,300/month); coverage varies significantly by plan and indication.
What Are These Medications and How Do They Work?
When patients and clinicians discuss Ozempic vs Mounjaro weight loss outcomes, they are comparing two subcutaneous injectable peptides that belong to the incretin-based therapy class — but with an important pharmacological distinction.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the endogenous incretin hormone GLP-1, which is released from intestinal L-cells after eating. By activating GLP-1 receptors in the pancreas, gut, and central nervous system, semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and — critically for weight management — reduces appetite through hypothalamic signaling. Semaglutide is marketed as Ozempic (0.25 mg, 0.5 mg, 1 mg, and 2 mg doses for type 2 diabetes) and as Wegovy (0.25 mg through 2.4 mg for chronic weight management).
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist — the first approved drug in this class. By engaging both incretin pathways simultaneously, tirzepatide produces additive or synergistic effects on insulin secretion, glucagon regulation, appetite suppression, and energy expenditure. It is marketed as Mounjaro (for type 2 diabetes) and as Zepbound (for chronic weight management), available in doses from 2.5 mg to 15 mg.
The dual-agonist mechanism of tirzepatide is thought to account for its generally greater efficacy in both glycemic control and weight reduction, though the precise contribution of GIP receptor activation remains an active area of research.
Clinical Evidence: STEP vs SURMOUNT Trials
The evidence base for semaglutide vs tirzepatide in weight management rests primarily on two landmark trial programs: STEP (Semaglutide Treatment Effect in People with Obesity) and SURMOUNT (for tirzepatide). While no single head-to-head trial has compared the two drugs at their approved weight-management doses in a non-diabetic obesity population, the trial data allow a reasonable indirect GLP-1 comparison.
Semaglutide — STEP Program Highlights
The STEP program enrolled adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. All participants received lifestyle intervention alongside the study drug.
- STEP 1 (N = 1,961): Semaglutide 2.4 mg once weekly produced a mean body weight reduction of –14.9% versus –2.4% with placebo at 68 weeks. Approximately one-third of participants lost ≥20% of body weight.
- STEP 2 (N = 1,210, participants with type 2 diabetes): Mean weight loss was –9.6% with semaglutide 2.4 mg versus –3.4% with placebo at 68 weeks — a lower magnitude, consistent with the known attenuation of weight-loss efficacy in patients with diabetes.
- STEP 5 (N = 304): Over a longer 104-week treatment period, semaglutide 2.4 mg achieved a sustained –15.2% mean weight loss, demonstrating durability of effect.
Tirzepatide — SURMOUNT Program Highlights
The SURMOUNT trials enrolled a similar population with comparable inclusion criteria.
- SURMOUNT-1 (N = 2,539): Tirzepatide at 5 mg, 10 mg, and 15 mg doses achieved mean weight reductions of –15.0%, –19.5%, and –20.9%, respectively, versus –3.1% with placebo at 72 weeks. Over half of participants on the 15 mg dose lost ≥20% of body weight.
- SURMOUNT-2 (N = 938, participants with type 2 diabetes): Mean weight loss was –12.8% (10 mg) and –14.7% (15 mg) versus –3.2% with placebo — notably greater than what semaglutide achieved in a comparable diabetic population.
- SURMOUNT-4 (N = 670): Demonstrated that weight regain occurs upon discontinuation — participants who switched from tirzepatide to placebo after 36 weeks regained approximately half the lost weight over the subsequent 52 weeks, underscoring the need for continued therapy.
Weight Loss Comparison Table
| Outcome | Semaglutide 2.4 mg (STEP 1) | Tirzepatide 5 mg (SURMOUNT-1) | Tirzepatide 10 mg (SURMOUNT-1) | Tirzepatide 15 mg (SURMOUNT-1) |
|---|---|---|---|---|
| Trial duration | 68 weeks | 72 weeks | 72 weeks | 72 weeks |
| Mean weight loss (%) | –14.9% | –15.0% | –19.5% | –20.9% |
| Mean weight loss (kg) | –15.3 kg | –16.1 kg | –22.2 kg | –23.6 kg |
| ≥5% weight loss | ~86% | ~85% | ~89% | ~91% |
| ≥10% weight loss | ~70% | ~66% | ~79% | ~84% |
| ≥20% weight loss | ~32% | ~30% | ~46% | ~57% |
| Placebo weight loss | –2.4% | –3.1% | –3.1% | –3.1% |
Key takeaway: At the lowest tirzepatide dose (5 mg), weight loss is roughly comparable to semaglutide 2.4 mg. At mid and high tirzepatide doses (10–15 mg), weight loss is substantially greater — an additional 5–6 percentage points on average. These are cross-trial comparisons and should be interpreted with caution; patient populations, baseline BMI, and lifestyle interventions were not identical.
A1c Reduction in Type 2 Diabetes
For patients with comorbid type 2 diabetes, glycemic efficacy matters alongside weight loss. In the SURPASS-2 trial, tirzepatide demonstrated A1c reductions of –2.0% (5 mg), –2.2% (10 mg), and –2.3% (15 mg) versus –1.9% for semaglutide 1 mg at 40 weeks. This is the one completed head-to-head trial comparing these two agents, though it used semaglutide at its diabetes dose (1 mg), not its weight-management dose (2.4 mg).
Dosing Schedules and Titration
Both medications are administered as once-weekly subcutaneous injections, typically in the abdomen, thigh, or upper arm. Slow dose titration is essential to minimize gastrointestinal side effects. Understanding the Mounjaro dosing schedule versus the Ozempic schedule is important for patients and prescribers alike.
Dosing Titration Table
| Week | Semaglutide (Ozempic) | Semaglutide (Wegovy) | Tirzepatide (Mounjaro/Zepbound) |
|---|---|---|---|
| Weeks 1–4 | 0.25 mg | 0.25 mg | 2.5 mg |
| Weeks 5–8 | 0.5 mg | 0.5 mg | 5 mg |
| Weeks 9–12 | Maintenance or ↑ to 1 mg | 1 mg | 7.5 mg |
| Weeks 13–16 | 1 mg (max for diabetes) or ↑ to 2 mg | 1.7 mg | 10 mg |
| Weeks 17–20 | 2 mg (max) | 2.4 mg (maintenance) | 12.5 mg |
| Week 21+ | — | — | 15 mg (max) |
| Min. time to max dose | ~16 weeks | ~16 weeks | ~20 weeks |
Practical dosing notes:
- Do not rush titration. The escalation schedule exists to allow GI adaptation. Patients who experience persistent nausea or vomiting should remain at their current dose for an additional 4 weeks before escalating.
- Missed doses: If fewer than 5 days have elapsed since the missed dose (for semaglutide) or fewer than 4 days (for tirzepatide), administer the injection as soon as possible. If more time has passed, skip the dose and resume on the regular schedule.
- Injection day flexibility: Both drugs allow patients to change their injection day as long as the last dose was administered at least 2 days (semaglutide) or 3 days (tirzepatide) earlier.
- Storage: Both are stored refrigerated (2–8°C) before first use. After first use, the pen can be kept at room temperature (up to 30°C) for up to 56 days (semaglutide) or 21 days (tirzepatide).
- Ozempic is FDA-approved only for type 2 diabetes. Its off-label use for weight loss is widespread, but the weight-management–approved formulation of semaglutide is Wegovy (2.4 mg). Similarly, Mounjaro is approved for type 2 diabetes, while Zepbound is the weight-management formulation of tirzepatide.
Side Effects and Tolerability
Gastrointestinal adverse events are the most common side effects of both medications and represent the primary reason for treatment discontinuation. Most GI symptoms are dose-related and tend to diminish after the first 8–12 weeks of treatment.
Common Side Effects
| Side Effect | Semaglutide 2.4 mg (STEP 1) | Tirzepatide 15 mg (SURMOUNT-1) |
|---|---|---|
| Nausea | 44% | 33% |
| Diarrhea | 30% | 23% |
| Vomiting | 24% | 13% |
| Constipation | 24% | 11% |
| Abdominal pain | 12% | 9% |
| Injection site reaction | ~3% | ~7% |
| Discontinuation due to AEs | ~7% | ~6% |
Nausea rates appear higher with semaglutide in these cross-trial comparisons, though differences in reporting methodology make direct comparison imperfect. Both drugs show improved tolerability with gradual titration.
Less Common but Clinically Significant Adverse Effects
- Pancreatitis: Rare but reported with all GLP-1 receptor agonists. Patients should be counseled to report severe, persistent abdominal pain radiating to the back. Both drugs are contraindicated in patients with a personal history of pancreatitis (per some guidelines; FDA labeling advises caution rather than absolute contraindication).
- Gallbladder events: Cholelithiasis and cholecystitis occur at higher rates with rapid weight loss. STEP 1 reported gallbladder-related events in approximately 2.6% of semaglutide-treated patients versus 1.2% with placebo.
- Hypoglycemia: Rare as monotherapy. Risk increases substantially when combined with sulfonylureas or insulin — dose reduction of concomitant hypoglycemic agents is usually necessary.
- Gastroparesis/delayed gastric emptying: Both drugs slow gastric motility. This may be clinically relevant before procedures requiring anesthesia. The American Society of Anesthesiologists has recommended considering holding GLP-1 agonists before elective surgery, though guidance continues to evolve.
- Retinopathy complications (semaglutide): The SUSTAIN-6 cardiovascular outcomes trial observed a higher rate of retinopathy complications with semaglutide in patients with pre-existing diabetic retinopathy. This signal has not been observed with tirzepatide, though longer follow-up is needed.
- Changes in body composition: Both drugs reduce both fat mass and lean mass. Resistance training and adequate protein intake (≥1.2 g/kg/day of ideal body weight) are recommended to preserve lean mass during pharmacotherapy-assisted weight loss.
Contraindications and Drug Interactions
| Contraindication/Caution | Semaglutide | Tirzepatide |
|---|---|---|
| Personal/family history of medullary thyroid carcinoma (MTC) | Contraindicated | Contraindicated |
| Multiple endocrine neoplasia syndrome type 2 (MEN2) | Contraindicated | Contraindicated |
| History of pancreatitis | Use with caution | Use with caution |
| Severe gastroparesis | Avoid | Avoid |
| Pregnancy | Discontinue ≥2 months before planned conception | Discontinue ≥2 months before planned conception |
| End-stage renal disease (eGFR <15) | Limited data; use with caution | Limited data; use with caution |
Drug interactions: Both agents delay gastric emptying, which can affect the absorption of concomitant oral medications. This is most clinically relevant for drugs with narrow therapeutic windows or those requiring rapid absorption. Patients on oral contraceptives should be aware of potential reduced efficacy during dose escalation periods (particularly relevant for tirzepatide; the FDA label recommends a backup contraceptive method or switching to a non-oral formulation during titration and for 4 weeks after each dose increase). Dose adjustment of insulin or sulfonylureas is generally required to prevent hypoglycemia.
Special Populations
Older Adults (≥65 years)
No dose adjustment is required for either drug based on age alone. However, older adults may be more susceptible to GI-related dehydration and should be counseled on adequate fluid intake. The risk of sarcopenic obesity — where excessive lean mass loss compounds age-related muscle decline — is a particular concern. Structured resistance exercise should be strongly encouraged.
Renal Impairment
Neither semaglutide nor tirzepatide requires dose adjustment in mild-to-moderate renal impairment. Transient decreases in eGFR have been reported with both agents, generally attributed to volume depletion from GI side effects. Adequate hydration monitoring is essential.
Hepatic Impairment
No dose adjustments are required. Both drugs have been studied in mild-to-moderate hepatic impairment without clinically significant pharmacokinetic changes.
Adolescents
Semaglutide (as Wegovy) is approved by the FDA for weight management in adolescents aged ≥12 years with obesity. The STEP TEENS trial demonstrated a –16.1% change in BMI with semaglutide versus +0.6% with placebo over 68 weeks. Tirzepatide does not currently hold FDA approval for adolescents in the weight-management indication, though trials are underway.
Pregnancy and Breastfeeding
Both semaglutide and tirzepatide are contraindicated in pregnancy. Animal studies have shown embryotoxicity. Given semaglutide's half-life of approximately 7 days and tirzepatide's half-life of approximately 5 days, a washout period of at least 2 months before attempting conception is recommended. There are insufficient data on excretion in human breast milk; breastfeeding is not recommended during treatment.
Cost, Insurance, and Access
Cost remains a significant barrier for both medications, and the distinction between diabetes and weight-management indications has major implications for coverage.
List prices (approximate U.S. figures as of early 2026):
- Ozempic: ~$900–$1,000/month
- Wegovy: ~$1,300/month
- Mounjaro: ~$1,000–$1,100/month
- Zepbound: ~$1,000–$1,100/month
Insurance considerations:
- Most commercial plans cover Ozempic and Mounjaro for type 2 diabetes with prior authorization.
- Coverage for Wegovy and Zepbound (weight-management indications) is far less consistent. Many plans exclude anti-obesity medications entirely or impose strict criteria (documented BMI, failed lifestyle intervention, comorbidity requirements).
- Medicare Part D has historically excluded coverage for anti-obesity medications, though this policy is under active legislative review. The Treat and Reduce Obesity Act, if passed, would expand Medicare coverage.
- Manufacturer savings programs (e.g., Eli Lilly's savings card for Zepbound, Novo Nordisk's patient assistance for Wegovy) can reduce out-of-pocket costs substantially for commercially insured patients, sometimes to $25–$150/month.
Supply considerations: Both medications have experienced intermittent supply shortages since their launch, driven by demand exceeding manufacturing capacity. Patients should discuss backup plans with their prescriber in case their preferred dose is temporarily unavailable.
Red Flags — When to Seek Immediate Medical Attention
Patients taking either semaglutide or tirzepatide should seek urgent medical care if they experience any of the following:
- Severe abdominal pain that is persistent, radiates to the back, or is accompanied by vomiting — may indicate pancreatitis
- Signs of anaphylaxis or serious allergic reaction: facial/throat swelling, difficulty breathing, severe rash, rapid heartbeat
- Symptoms of gallbladder disease: sudden right upper quadrant pain, fever, jaundice
- Severe hypoglycemia (especially if taking concomitant insulin or sulfonylureas): confusion, loss of consciousness, seizures
- Signs of significant dehydration: minimal urine output, dark urine, dizziness, rapid heart rate — particularly in the context of prolonged vomiting or diarrhea
- Visual changes in patients with pre-existing diabetic retinopathy (semaglutide)
- A lump or swelling in the neck, difficulty swallowing, persistent hoarseness — although the thyroid C-cell tumor risk is based on rodent data, patients should report these symptoms
Frequently Asked Questions
Which is better, Ozempic or Mounjaro, for weight loss? Based on available clinical trial data, tirzepatide (Mounjaro/Zepbound) produces greater average weight loss at its mid-to-high doses (10–15 mg) compared with semaglutide (Ozempic/Wegovy) at 2.4 mg. However, "better" depends on individual factors including tolerability, insurance coverage, cost, and prescriber experience. Some patients respond exceptionally well to semaglutide. The best medication is the one a patient can access, tolerate, and continue long-term.
Can I switch from Ozempic to Mounjaro (or vice versa)? Yes, switching is clinically feasible. Most prescribers start the new agent at the beginning of its titration schedule (tirzepatide 2.5 mg or semaglutide 0.25 mg) to minimize GI side effects, though some may begin at a slightly higher dose depending on prior tolerability. Discuss timing and approach with your prescriber.
Do I need to have diabetes to take these medications? No. Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are specifically approved for chronic weight management in adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity, regardless of diabetes status. Ozempic and Mounjaro carry diabetes-specific approvals.
What happens when I stop taking the medication? Weight regain is common after discontinuation. The SURMOUNT-4 trial demonstrated that participants who switched from tirzepatide to placebo regained roughly half of their lost weight within one year. Similar findings have been observed with semaglutide. Current guidelines increasingly view obesity as a chronic disease requiring ongoing pharmacotherapy, much like hypertension or dyslipidemia.
How quickly will I see results? Most patients notice meaningful weight loss within the first 12–16 weeks. However, the full effect of both drugs is typically observed at 40–72 weeks of treatment at maintenance doses. Early GI side effects may cause initial weight reduction that is partly fluid-related; fat mass loss accelerates as the dose is optimized.
Can I take either drug if I have a history of eating disorders? This requires careful clinical evaluation. While appetite-suppressing medications may seem counterintuitive in patients with eating disorder histories, some obesity medicine specialists do prescribe them with close psychiatric monitoring. Both drugs should be avoided in patients with active anorexia nervosa or bulimia nervosa. Discuss your full history openly with your prescriber.
Are compounded versions of semaglutide or tirzepatide safe? The FDA has issued warnings about compounded versions of these drugs. Compounded products are not FDA-approved, may contain different salt forms (e.g., semaglutide sodium vs. semaglutide base), and have not undergone the same rigorous testing for sterility, potency, and stability. While compounding pharmacies fill an important role during drug shortages, patients should use FDA-approved products whenever possible.
Do these drugs increase the risk of thyroid cancer in humans? Both drugs carry a boxed warning regarding thyroid C-cell tumors based on rodent studies. However, the relevance of this finding to humans is uncertain — rodents have far more GLP-1 receptors on thyroid C-cells than humans. No causal link to medullary thyroid carcinoma has been established in human clinical trials or post-marketing surveillance to date. Nevertheless, both medications remain contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
References
-
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
-
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024
-
Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647
-
Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. PMID: 33667417
-
Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. PMID: 37385275
-
Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. PMID: 38078870
-
Weghuber D, Barrett T, Engberg S, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245-2257. PMID: 36322838
-
FDA. Prescribing information: Ozempic (semaglutide) injection. 2017 (updated 2024). accessdata.fda.gov
-
FDA. Prescribing information: Mounjaro (tirzepatide) injection. 2022 (updated 2024). accessdata.fda.gov
-
Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA. 2021;325(14):1414-1425. PMID: 33755728
About the Author
Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with over 15 years of experience in ambulatory care, medication therapy management, and patient education. He has practiced in hospital, community, and outpatient clinic settings, with particular expertise in cardiometabolic disease management, including diabetes, obesity, and dyslipidemia pharmacotherapy. Dr. Ozarchuk writes for PillsCard.com to provide evidence-based, accessible drug information that helps patients and caregivers make informed decisions alongside their healthcare providers.
Medical Disclaimer
This article is intended for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented reflects current evidence and guidelines at the time of writing but may not account for individual clinical circumstances. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Do not disregard professional medical advice or delay seeking treatment based on information in this article. PillsCard.com and the author assume no liability for actions taken based on the content provided herein.